Insulin in type 2 diabetes: getting the balancing act rightKaret BBritish Journal of Primary Care Nursing. Cardiovascular Disease & Diabetes
Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes. Diabetes Care 37, 751–759 (2014). Article PubMed PubMed Central CAS Google Scholar Reger, M. A. et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE ...
SKYLER J.S. ET AL: ' Insulin therapy in type II diabetes. ' POSTGRADUATE MEDICINE., [Online] vol. 101, no. 2, February 1997, pages 1 - 17, XP002080749 Retrieved from the Internet:Skyler JS. Insulin therapy in type II diabetes: who needs it, how much of it and for how long?
Clinical trials have shown that insulin analogues, such as glargine, detemir, aspart, and lispro, do not offer major advantages over human insulin products, such as neutral protamine Hagedorn (NPH) and regular human insulin, for patients with type 2 diabetes.1,2In these studies, neithe...
Insulin therapy in type 2 diabetesJill Hill
March 14, 2012 — The addition of insulin to the treatment regimen of patients with type 2 diabetes does not significantly increase the incidence of vascular events, according to a study involving nearly 15,000 participants. Any perceived differences in vascular events between the 2 groups is ...
Insulin resistance and impaired insulin secretion are the main pathophysiological defects responsible for the development of hyperglycemia in type 2 diabetes.[1,2]With the continuous presence of insulin resistance, progressive loss of β-cell function is the crucial defect. The continuous decline in β...
Learn how to control type 2 diabetes with SOLIQUA 100/33, which goes beyond insulin and lowers A1C with diet and exercise in adults. See Important Safety Information.
Tandem is following competitor Insulet’s lead with the second automated insulin delivery system indicated for Type 2 diabetes.
development of insulin antibodies and changes in pulmonary function with long-term use. If inhaled insulin is approved by the FDA, it will represent another therapeutic option for patients with type 2 diabetes, but primary care physicians will need guidance in selecting appropriate candidates for the...